智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)收到国家药品监督管理局颁发的关于瑞舒伐他汀依折麦布片(Ⅰ)的《药品注册证书》(证书编号：2026S02581)，该药品获得批准生产。
瑞舒伐他汀依折麦布片适用于高胆固醇血症或纯合子型家族性高胆固醇血症(HoFH)，由Sanofi-aventis,S.R.O.公司开发，2014年07月在欧盟上市，商品名为Zenon Neo。2024年12月，常州制药厂有限公司就该药品向国家药监局提出注册上市申请，并获受理。截至公告日，公司针对该药品已投入研发费用约人民币968万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.